Abstract:Small GTPase RhoA is a key signaling component regulating cell migration and stress fiber formation. Previous studies have shown that RhoA activity is regulated by protein kinases, such as cAMP-dependent protein kinase (PKA) and type I cGMP-dependent protein kinase (PKGI), which phosphorylate the protein. This study was designed to investigate the effect of type II cGMP-dependent protein kinase (PKGII) on RhoA activity. Cells of the human gastric cancer line AGS were infected with adenoviral constructs bearing the PKGII cDNA in order to increase its endogenous expression, and were treated with 8-pCPT-cGMP to activate the PKGII enzyme. A transwell assay was performed to measure the migratory activity of the treated cells, and immunofluorescent microscopy was used to observe the formation of stress fibers. The phosphorylation of RhoA was detected by western blotting, and the activity of RhoA was measured by a pull-down assay. Co-immunoprecipitation (co-IP) was performed to detect binding of PKGII to RhoA. Glutathione S-transferase (GST)-fused fragments of RhoA and PKGII were expressed in Escherichia coli and used to investigate the domains required for the binding. The results showed that lysophosphatidic acid (LPA) treatment increased the migration and the formation of stress fibers in AGS cells and that this effect was RhoA-dependent. An increase in PKGII activity, not only inhibited LPA-induced migration and stress fiber formation, but also suppressed LPA-induced activation of RhoA. PKGII caused serine 188 (Ser188) phosphorylation of RhoA, but not the phosphorylation of the mutant RhoA Ser188A, and therefore had no inhibitory effect on the activity of the mutant protein. Co-IP results showed that there is direct binding of PKGII to RhoA. The GST pull-down assay showed that the fragment containing RhoA amino acid residues 1-44 and the N-terminal fragment of PKGII containing amino acid residues 1-176 are required for the binding between the two proteins. These results suggested that PKGII inhibits RhoA activity by binding to this small GTPase and causing phosphorylation at its Ser188 site.

Type II Cgmp-Dependent Protein Kinase Phosphorylates EGFR at Threonine 669 and Thereby Inhibits Its Activation.

Type II cGMP-dependent protein kinase inhibits ligand‑induced activation of EGFR in gastric cancer cells.

cGMP-dependent protein kinase (PKG II) inhibits epidermal growth factor (EGF)-induced MAPK/ERK and MAPK/JNK-mediated signal transduction through the inhi- bition of the phosphorylation/activation of the EGF receptor

Type II cGMP-dependent protein kinase inhibits epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt signal transduction in gastric cancer cells.

Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines.

Pkg Ii Inhibits Pdgf-Bb Triggered Biological Activities By Phosphorylating Pdgfr In Gastric Cancer Cells

Type II Cgmp-Dependent Protein Kinase Directly Inhibits HER2 Activation of Gastric Cancer Cells.

Type Ii Cgmp-Dependent Protein Kinase Inhibits Activation Of Key Members Of The Rtk Family In Gastric Cancer Cells

PKG II Inhibits EGF/EGFR-induced Migration of Gastric Cancer Cells.

Type II Cyclic Guanosine Monophosphate-Dependent ProteinKinase Inhibits Vegf-A/Vegfr-2 Pathway Activation in GastricCancer Cells

Type II Cgmp-Dependent Protein Kinase Inhibits EGF-induced MAPK/JNK Signal Transduction in Breast Cancer Cells

Type Ii Cgmp-Dependent Protein Kinase Inhibits Egf-Induced Jak/Stat Signaling in Gastric Cancer Cells

PKG II Effectively Reversed EGF-induced Protein Expression Alterations in Human Gastric Cancer Cell Lines.

Type Ii Cgmp-Dependent Protein Kinase Inhibits Erk/Jnk-Mediated Activation of Transcription Factors in Gastric Cancer Cells

PKG II Reverses HGF-triggered Cellular Activities by Phosphorylating Serine 985 of C-Met in Gastric Cancer Cells

Type Ii Cgmp-Dependent Protein Kinase Inhibits the Migration, Invasion and Proliferation of Several Types of Human Cancer Cells

The constitutively active PKG II mutant effectively inhibits gastric cancer development a blockade of EGF/EGFR-associated signalling cascades.

Secretory type II cGMP-dependent protein kinase blocks activation of PDGFR beta via Ser254 in gastric cancer cells

PKG II secreted via the classical endoplasmic reticulum-Golgi apparatus secretory pathway blocks the activation of EGFR through phosporalting its threonine 406 and has an anti-tumor effect

Type II cGMP‑dependent protein kinase inhibits RhoA activation in gastric cancer cells.

Endogenous Cgmp-Dependent Protein Kinase Reverses EGF-induced MAPK/ERK Signal Transduction Through Phosphorylation of VASP at Ser239.